Benitec Biopharma Ltd ADR (BNTC)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Benitec Biopharma Ltd ADR.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 11.70 $ — 25% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 106.6% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 7
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 06/30/2027 | -1.14 | -1.29 – -1.02 | 18 | – | 4 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.28 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.28 | – | 0 | – | – | -8 | -8 |
| 2025: Q1 | -0.42 | – | 0 | -100.00 | – | -3 | -3 |
| 2025: Q2 | -0.47 | – | 1 | – | -2,904.10 | -9 | -9 |
| 2025: Q3 | -0.26 | – | 0 | – | – | -3 | -3 |
| 2025: Q4 | -0.34 | – | 0 | – | – | -4 | -4 |
| 2026: Q1 | -0.35 | – | 0 | – | – | -5 | -5 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | -19 | -14 | -123.69 | -20 | 14 | 20 |
| 2017 | 0 | -16 | -6 | -40.72 | -8 | 22 | 23 |
| 2018 | 4 | -9 | -12 | -74.68 | -10 | 14 | 21 |
| 2019 | 17 | 4 | 4 | 18.51 | 5 | 17 | 28 |
| 2020 | 0 | -8 | -8 | -34.43 | -8 | 10 | 12 |
| 2021 | 0 | -14 | -14 | -13.74 | -13 | 20 | 21 |
| 2022 | 0 | -18 | -18 | -9.47 | -16 | 3 | 6 |
| 2023 | 0 | -19 | -20 | -14.12 | -18 | 0 | 4 |
| 2024 | 0 | -22 | -22 | -2.12 | -19 | 47 | 52 |
| 2025 | 0 | -42 | -38 | -1.05 | -24 | 97 | 100 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Benitec Biopharma Inc., ein Biotechnologieunternehmen in der klinischen Phase, konzentriert sich auf die Entwicklung neuartiger genetischer Medizin.
| Employees | 19 |
|---|---|
| Headquarters | Hayward, CA |
| Address | 3940 Trust Way, 94545 Hayward, United States |
| Phone | 510 780 0819 |
| Website | benitec.com |
| IPO Date | 18. Aug 2015 |
| ISIN | US08205P2092 |
| Stock Split | 1:17 on 07/26/2023 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jerel A. Banks M.D., Ph.D. | Executive Chairman & CEO | 1976 |
| Megan Joan Boston B.Com., C.A. | CFO & Secretary | 1973 |
| Sophie Mukadam | Chief Operating Officer | 1981 |
| Michael Graham | Head of Discovery & Founding Scientist | – |
| Claudia Kloth Ph.D. | Senior Vice President of Manufacturing | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.